Melanoma/Skin Cancer News

Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.

The FDA granted priority review to two cancer treatment regimens.

Black patients with earlier-stage melanoma were more likely than their non-Hispanic white counterparts to experience delayed time from diagnosis to definitive surgery, according to a study.

Patients with cancer enrolled in a supportive oncodermatology program experienced a significant improvement in quality of life, according to a study.

Lymph node status is a predictor of survival in patients with vulvar melanoma and vaginal melanoma, according to a study published in American Journal of Clinical Dermatology.

Nivolumab administered 4 weeks before surgery induced pathologic complete responses and radiographic tumor regressions in about half of a cohort of patients with Merkel cell carcinoma, according to results of the phase 1/phase 2 CheckMate 358 study published in Journal of Clinical Oncology.

The FDA has approved Nevisense 3.0, an artificial intelligence system for early melanoma detection, SciBase announced in a press release.

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.

Researchers from the Department of Epidemiology at University of California, Irvine, found that age is a factor in the interaction between sex and ultraviolet index in melanoma.

An alternative pembrolizumab dosing regimen of 400 mg every 6 weeks appeared safe and effective for patients with metastatic melanoma, according to first clinical outcomes data from KEYNOTE-555 cohort B presented at the virtual American Association for Cancer Research Annual Meeting.